FDA Approves Humira
FDA Approves Humira for Rheumatoid Arthritis
Humira is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for reducing the signs and symptoms, inducing major clinical response, slowing the progression of joint damage, and improving physical function in adult patients with moderate to severe rheumatoid arthritis.Related Articles:
Abbott Receives FDA Approval for Humira (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis - February 22, 2008
Abbott's Humira (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis - January 22, 2008
Humira (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease - February 27, 2007
Humira Receives FDA Approval for Treatment of Ankylosing Spondylitis - July 31, 2006
Humira Receives FDA Approval for Psoriatic Arthritis - October 4, 2005
FDA Drug Approvals Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Aug | Oct | Dec
